Adagio Medical Holdings, Inc Common Stock (ADGM)vsAstraZeneca PLC (AZN)
ADGM
Adagio Medical Holdings, Inc Common Stock
$1.05
-3.67%
HEALTHCARE · Cap: $23.32M
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 42875082% more annual revenue ($58.74B vs $137,000). AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
ADGM
Hold37
out of 100
Grade: F
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADGM.
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 75.6% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ADGM
The strongest argument for ADGM centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 75.6% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bear Case : ADGM
The primary concerns for ADGM are EPS Growth, Market Cap, Profit Margin.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Key Dynamics to Monitor
ADGM profiles as a hypergrowth stock while AZN is a value play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.28 — expect wider price swings.
ADGM is growing revenue faster at 75.6% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 37/100), backed by strong 17.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adagio Medical Holdings, Inc Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Adagio Medical Holdings, Inc. is a cutting-edge biotechnology company focused on developing advanced medical technologies for the treatment of cardiac arrhythmias. By leveraging its proprietary platform, Adagio is pioneering innovative targeted ablation techniques that fulfill significant gaps in the electrophysiology market. With a promising product pipeline and an experienced leadership team, the company offers a compelling investment opportunity for institutional investors seeking to participate in the rapidly evolving healthcare landscape and enhance patient care in the cardiac domain.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?